share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

SEC announcement ·  Apr 3 17:44
Summary by Moomoo AI
Blake Borgeson, a key figure at Recursion Pharmaceuticals, completed a sale of 11,447 shares of the company's Class A Common Stock on April 2, 2024. The transaction was carried out on the open market at a price of $8.8182 per share, resulting in a total sale value of approximately $100,941.94. Following the sale, Borgeson's direct holdings in Recursion Pharmaceuticals amount to 7,241,308 shares. This sale reflects a transaction within the normal course of trading activities for individuals with significant holdings in publicly traded companies.
Blake Borgeson, a key figure at Recursion Pharmaceuticals, completed a sale of 11,447 shares of the company's Class A Common Stock on April 2, 2024. The transaction was carried out on the open market at a price of $8.8182 per share, resulting in a total sale value of approximately $100,941.94. Following the sale, Borgeson's direct holdings in Recursion Pharmaceuticals amount to 7,241,308 shares. This sale reflects a transaction within the normal course of trading activities for individuals with significant holdings in publicly traded companies.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more